Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ).
Shanghai Fosun Pharmaceutical announced that its subsidiary, Jisimei (Wuhan) Pharmaceutical Co., Ltd., has had its drug registration application for Vincristine Sulfate Injection accepted by the National Medical Products Administration. This drug, developed independently by the company, is intended for the treatment of various cancers, including acute leukemia and Hodgkin lymphoma. The acceptance marks a significant step in the company’s R&D efforts, having invested approximately RMB3.03 million in the drug’s development, potentially enhancing its position in the oncology market.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$17.20 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company incorporated in China, operating in the pharmaceutical industry. The company focuses on the development and manufacturing of pharmaceutical products, with a market emphasis on innovative drugs and healthcare services.
Average Trading Volume: 10,877,098
Technical Sentiment Signal: Hold
Current Market Cap: HK$79.26B
Learn more about 2196 stock on TipRanks’ Stock Analysis page.